Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roivant Sciences Ltd. - Common Shares (NQ:ROIV)

27.84 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 442
Open 27.84
Bid (Size) 26.00 (100)
Ask (Size) 27.50 (200)
Prev. Close 27.84
Today's Range 27.84 - 27.84
52wk Range 8.730 - 30.33
Shares Outstanding 692,072,184
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
From Roivant Sciences
Via GlobeNewswire

Performance

YTD
+26.9%
+26.9%
1 Month
-0.9%
-0.9%
3 Month
+28.4%
+28.4%
6 Month
+76.8%
+76.8%
1 Year
+182.6%
+182.6%

More News

Read More
News headline image
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
News headline image
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you? ↗
Via The Motley Fool
Why Did Roivant Sciences Stock Gain 9% Pre-Market Today? ↗
Via Stocktwits
News headline image
Moderna Settles High-Stakes LNP Patent War with $2.25 Billion Agreement
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
BlackBarn Capital Builds Warby Parker Stake as the Direct-to-Consumer Eyewear Leader Expands Nationwide ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock ↗
Via Stocktwits
Topics Intellectual Property
News headline image
MRNA Shares Rally After Hours On Inking Settlement Deal Over Vaccine Patent Row ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
From Arbutus Biopharma Corporation
Via GlobeNewswire
News headline image
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
From Roivant Sciences
Via GlobeNewswire
News headline image
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis
From Roivant Sciences
Via GlobeNewswire
News headline image
Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
Via The Motley Fool
News headline image
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
TTMI Stock Soars 250% in One Year, and One Fund Is Betting $7 Million on More Growth ↗
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
News headline image
Healthcare REIT Posts 16.4% NOI Growth as Shares Soar 93%: Why This Fund's New Stake Stands Out ↗
Via The Motley Fool
Topics Regulatory Compliance
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
Via Finterra
Topics ETFs Economy Initial Public Offering
Get insights into the top gainers and losers of Friday's pre-market session. ↗
Via Chartmill
News headline image
Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
From Roivant Sciences
Via GlobeNewswire
News headline image
Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Pulmovant, Inc.
Via GlobeNewswire
News headline image
Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
From Roivant Sciences
Via GlobeNewswire
News headline image
The Great Rotation: Russell 2000’s Historic 15-Day Streak Marks a Seismic Shift in Market Leadership
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
From Roivant Sciences
Via GlobeNewswire

Frequently Asked Questions

Is Roivant Sciences Ltd. - Common Shares publicly traded?
Yes, Roivant Sciences Ltd. - Common Shares is publicly traded.
What exchange does Roivant Sciences Ltd. - Common Shares trade on?
Roivant Sciences Ltd. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Roivant Sciences Ltd. - Common Shares?
The ticker symbol for Roivant Sciences Ltd. - Common Shares is ROIV on the Nasdaq Stock Market
What is the current price of Roivant Sciences Ltd. - Common Shares?
The current price of Roivant Sciences Ltd. - Common Shares is 27.84
When was Roivant Sciences Ltd. - Common Shares last traded?
The last trade of Roivant Sciences Ltd. - Common Shares was at 04/01/26 04:00 PM ET
What is the market capitalization of Roivant Sciences Ltd. - Common Shares?
The market capitalization of Roivant Sciences Ltd. - Common Shares is 19.27B
How many shares of Roivant Sciences Ltd. - Common Shares are outstanding?
Roivant Sciences Ltd. - Common Shares has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.